PISKEL KYLE 4
4 · Adaptive Biotechnologies Corp · Filed Jan 14, 2026
Insider Transaction Report
Form 4
PISKEL KYLE
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-01-12$12.14/sh+4,290$52,081→ 220,927 total - Sale
Common Stock
[F1]2026-01-12$18.00/sh−4,290$77,220→ 216,637 total - Exercise/Conversion
Stock Option (right to buy)
[F1][F2]2026-01-12−4,290→ 4,291 totalExercise: $12.14Exp: 2032-03-04→ Common Stock (4,290 underlying)
Footnotes (2)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025.
- [F2]The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Signature
/s/ Kyle Piskel|2026-01-14